A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Armstrong, Andrew J; Netto, George J; Rudek, Michelle A; Halabi, Susan; Wood, David P; Creel, Patricia A; Mundy, Kelly; Davis, S Lindsay; Wang, Ting; Albadine, Roula; Schultz, Luciana; Partin, Alan W; Jimeno, Antonio; Fedor, Helen; Febbo, Phillip G; George, Daniel J; Gurganus, Robin; De Marzo, Angelo M; Carducci, Michael A

Armstrong, Andrew J; Netto, George J; Rudek, Michelle A; Halabi, Susan; Wood, David P; Creel, Patricia A; Mundy, Kelly; Davis, S Lindsay; Wang, Ting; Albadine, Roula; Schultz, Luciana; Partin, Alan W; Jimeno, Antonio; Fedor, Helen; Febbo, Phillip G; George, Daniel J; Gurganus, Robin; De Marzo, Angelo M; Carducci, Michael A.

Affiliation

Armstrong AJ; Duke Comprehensive Cancer Center and Duke Prostate Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27710, USA. andrew.armstrong@duke.edu

Clin Cancer Res ; 16(11): 3057-66, 2010 Jun 01.

Article in En | MEDLINE | ID: mdl-20501622

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Protein Serine-Threonine Kinases / Sirolimus / Intracellular Signaling Peptides and Proteins Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google